Cerus Corporation (CERS)

[quannah]

BARDA Contract announcement today:
CONCORD, Calif., Dec 19, 2016 (BUSINESS WIRE) -- Cerus Corporation CERS, -1.63% announced today that additional options totaling $10,825,555 have been exercised under its contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response. The newly exercised options include funding for in vitro pathogen inactivation and red blood cell (RBC) function studies to support FDA licensure, as well as the manufacturing of clinical trial materials needed for a Phase III trial in the continental United States.

“The exercise of these additional options reflects the substantial progress our team has made in just a few short months since initiating activities related to this important contract with BARDA,” said Dr. Laurence Corash, Cerus’ chief scientific officer. “We are working closely with the FDA to reach an agreement on the protocol design for our Phase III trial, and this additional funding ensures that we can begin preparing the necessary clinical trials materials to move forward quickly upon such agreement.”
And yet the stock price went down. Looking at the chart would suggest that shorty is pushing it down.

[iwitness4jc]

11/25 report on CRERUS from Zolmax News:

Cerus Corp. (NASDAQ:CERS) has been given an average recommendation of “Buy” by the eight ratings firms that are covering the stock. Two equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $9.10.

CERS has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated a “buy” rating and issued a $9.00 target price on shares of Cerus Corp. in a report on Sunday, July 31st. BTIG Research reiterated a “buy” rating and issued a $10.00 target price on shares of Cerus Corp. in a report on Thursday, October 27th. FBR & Co reiterated an “outperform” rating and issued a $10.00 target price on shares of Cerus Corp. in a report on Thursday, August 11th. Zacks Investment Research cut Cerus Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, August 9th. Finally, Robert W. Baird set a $10.00 target price on Cerus Corp. and gave the stock a “buy” rating in a report on Saturday, August 6th.

Shares of Cerus Corp. (NASDAQ:CERS) opened at 5.76 on Thursday. The stock’s market capitalization is $595.96 million. The company has a 50-day moving average price of $5.47 and a 200 day moving average price of $6.03. Cerus Corp. has a 52 week low of $4.22 and a 52 week high of $7.64.

Cerus Corp. (NASDAQ:CERS) last announced its earnings results on Thursday, November 3rd. The company reported ($0.14) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.03. The firm earned $10.20 million during the quarter, compared to analysts’ expectations of $10.34 million. Cerus Corp. had a negative return on equity of 76.76% and a negative net margin of 174.76%. The company’s quarterly revenue was up 27.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.17) EPS. Equities analysts forecast that Cerus Corp. will post ($0.64) EPS for the current fiscal year.
In related news, CFO Kevin Dennis Green sold 17,150 shares of the firm’s stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $6.80, for a total transaction of $116,620.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 6.60% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Baker BROS. Advisors LP purchased a new stake in shares of Cerus Corp. during the third quarter worth $81,061,000. BlackRock Fund Advisors raised its stake in shares of Cerus Corp. by 5.6% in the third quarter. BlackRock Fund Advisors now owns 4,169,260 shares of the company’s stock worth $25,891,000 after buying an additional 219,507 shares during the period. Vanguard Group Inc. raised its stake in shares of Cerus Corp. by 12.7% in the second quarter. Vanguard Group Inc. now owns 4,104,732 shares of the company’s stock worth $25,613,000 after buying an additional 463,013 shares during the period. Peregrine Capital Management LLC purchased a new stake in shares of Cerus Corp. during the third quarter worth $20,642,000. Finally, Elk Creek Partners LLC raised its stake in shares of Cerus Corp. by 12.1% in the second quarter. Elk Creek Partners LLC now owns 2,763,235 shares of the company’s stock worth $8,747,000 after buying an additional 299,125 shares during the period. 67.69% of the stock is owned by institutional investors and hedge funds.

[starkd748]

Biotech is the only thing I trust American....f#¢k trump fu¢k Republicans .....Trudeau all the way with tmjF

[starkd748]

I own this board and I write whatever I want...go cgc twmjf and cers

[starkd748]

Loving Canada weed loving Trudeau.... Twmjf going up

[starkd748]

LNG term play splashing some water....maybe we make waves soon if trump backs biotechnology companies

[starkd748]

Wow coming back the imperial wizard may take us back up.....

[starkd748]

So basically short it if it hits 4.55 or lower...hmmmm looks like a short attack coming....

[starkd748]

Ha ha my longterm biotech

[ClayTrader]

* * $CERS Video Chart 11-04-16 * *

Link to Video - click here to watch the technical chart video

[mogman]

More positive news out from "The Street.com"

Cantor Fitzgerald analyst Bryan Brokmeier believes the spotlight on Brazil will benefit a company working on treatments for the Zika virus, like Cerus (CERS) . "Although there have been new announcements of the low risks of contracting Zika during the Olympics, Zika continues to make headlines and we believe that growing awareness and fear may drive shares of companies that are involved in combating Zika higher," he wrote. "CERS offers the only FDA approved pathogen inactivation technology and was recently included in the FDA guidance document for reducing the risk of transfusion-transmission of Zika...At least 12 babies in the U.S. have been born with microcephaly and other serious brain defects caused by Zika. That compares to more than 4,000 babies born in Brazil. More importantly, peak mosquito season just passed in Brazil so most infected babies haven't yet been born - according to multiple recent articles, 40,000 infected babies are expected to be born in Brazil. In our view, a few special reports during the Olympics on Zika and the babies born with microcephaly may be sufficient to create a national outcry over the need to combat Zika in the U.S, which would further support shares of CERS."

Page 3 of 6

https://www.thestreet.com/story/13674386/3/which-stocks-are-impacted-by-the-rio-olympics.html

[starkd748]

Thanks...I sold some at a little profit still my long term..I thought this would pop..ill add some 6s or high 5s to my pile if it gets that low...my Canadian weed play is doin wonderful.. Listed on the tsx ...the only legit weed ticker on a reputable exchange

[starkd748]

Thanks...I sold some at a little profit still my long term..I thought this would pop..ill add some 6s or high 5s to my pile if it gets that low...my Canadian weed play is doin wonderful.. Listed on the tsx ...the only legit weed ticker on a reputable exchange

[mogman]

The article....

http://www.newsmax.com/Health/Health-News/zika-blood-supply-protections/2016/07/28/id/741117/

[mogman]

Even with the TV, cable and print media exposure with Zika, the mention of Cerus specifically seems to be purposely omitted. Conspiracy or not.... that sucks!!!

I have found only one article in Newsmax Health that (halfway down and buried in text) cites Cerus as a true boon to transfusion using blood pathogen inactivation, thus negating testing. I quote.....

"The agency (FDA) has also approved a pathogen inactivation technology made by Cerus Corp that kills the virus in blood platelets and plasma. The company is conducting clinical trials to show it can also kill pathogens in red blood cells."

I will enclose the link in a subsequent post here because I am afraid if I include the link, the IH folks may delete the this whole post. GLTA

[starkd748]

Zika on CNN news allday sunday..the even did a story on a pregnant couple in the red zone are where zika was found....

[jadite]

I undestand your cautious attitude given the history here. I'm sticking with this because even if we are disappointed on 8/4, our disappointment will be slight and short-lived, given the current zika crisis and the confidence the U.S. government has shown in our role.

[Awesome A]

I am long on the stock. However, I have been disappointed many times - just when the stock seems to be gaining traction, it gets "disappointing" news with the quarterly report and the stock takes a significant hit.

For this rally to continue, I believe that the 8/4 quarterly report has to at least meet Wall Street expectations - otherwise, the price may drop back to the high 5's lower 6's.

As to the Zika Virus, I wonder if this (combined with a recent report from a pennystock "newsletter") is artificially inflating the stock price. A good second quarter result would bolster some confidence in this stock starting a consistent run higher (perhaps it may trigger the short squeeze a lot of us have been waiting for).

Finally, it would be nice to get FDA approval for red blood cells - then the full potential of the product could be realized.

[starkd748]

Feels good to be mod of a good stock....

[jadite]

You've owned it one year longer than I have! Patience.
I don't know about $11 but with BARDA funding, the zika nightmare, and management's reluctance to offer guidance, a big increase in pps is coming.
Best of luck to you and all CERS longs!

[mogman]

Call me an optimist (owned since March, 2009), I have a sneaky feeling that this could be over $11 on the 5th of August.

[jadite]

I have owned this for years too. I wasn't expecting much this earnings report but there may be a surprise. This company has an amazing future.

[starkd748]

I'm stilllll loading up hmmmmm boys...been here for yrs...

[sweetliberty1776]

Looks like this company has the right product

but management has been absent on the cnbc etc

especially while the whole zika virus attention has been out there

[Sub Atomic master]

Nice if we can close in the 670 areas

[starkd748]

Put another 1k in I think I'm goin for 2k tomorrow

[mogman]

A few moments ago just hit $6.52.

My question is.... Is this truly the awaited long ramp up?

This is such a pleasure to watch.

[mogman]

Might want to get a bigger dipper before consolidation at $6.

$180 million from USA Government plus $2 million raised from Swiss grant for Red Blood Cells (whole blood) pathogen inactivation in Africa.

All in about a week and CERS now has over $182 million dollars of non-dilutive assets allocated toward speeding up the process of global approval.

Pray that this is the start of a great relationship between investors and saving lives throughout the world.

[starkd748]

Yea lol its my hedge play I add here on dips

[mogman]

My, my, my, this has been a long nap hasn't it?

Getting over $7 is akin to a "Moms" Mabley humor quote.....

(Cerus) is like pushing an old car up a steep hill...... with a rope!

[starkd748]

Weeeeeeeeeeeeeee my hedge

[starkd748]

Mfdooooooom has spoken...buy all you can doooooooom..I win I'm the mod I'm #1 not like this turd plays....

[starkd748]

Go job to me and a few longs here...we're gonna bank hard here..zika virus play..its gonna get rough when the summer hits..weeeeeeeeeeeeee...my stinky pinkies get added here after I gain or lose...

[starkd748]

Weeeeeee

[starkd748]

Shorts gonna fry lol.....

[starkd748]

Yay picking up steam..I add all my profits from stinkies here lol..

[Sub Atomic master]

Yep

[starkd748]

Its coming alive RBC approval next...

[starkd748]

Nice longterm play

[starkd748]

Keep adding

[starkd748]

It looks fine to me....we should hit 6s soon...

[mogman]

Big day March 8, 2016, see if CERS brings any current quarter earnings into their report.

Tomorrow could be a winner or a wiener.

Any ideas of the outcome?

[bullrider2]

Volume has pick up. Expect for volume to increase when the market open today at 9:30am.

[BigTony1]

Looking forward to next week, hoping to move above $6, with good volume

[starkd748]

One of the few stocks I hold long term buy weekly on....

[mogman]

CERS + Baker Bros = Billions

Cerus, just like Synageva, will be swallowed up at over $200 per share through BB's assistance.

Synageva was formed when Sanj K. Patel was approached in early 2008 by Baker Bros. Investments.

On May 6, 2015, Alexion Pharmaceuticals (NASDAQ: ALXN) and Synageva announced that they entered into a definitive agreement in which Alexion would acquire Synageva for a value of $230 per share.

Similar action by BB and PCYC's share price moving up to $264 ps.

There is real HISTORY here with BB. Stay long and buy CERS IMO.

[starkd748]

Hmmmmm I'll scream like Richard Simmons and put a head band on then I'll aggravate a couple of my female coworkers... They are so funny I like picking at them...women are gods true gift to society lol....

[mogman]

Yep, the shorts are senseless. CERS down a bit but returned to -.08 from being downswept by the general market, nearly .29 down from prev close.

No telling where it will go in the next few weeks until the Feb news of the mandate for Intercept to kick in.

Glad you picked up more shares. Whenever it goes up it should be one heck of a ride. Baker Bros. had a big hand in PCYC also and that price went from about $6 to $261. The last $100 was over the course of a few months. Now that would be nice huh?

[starkd748]

U should see yahoo mb for laughs shorts are shaking in their boots making up posts lol

[starkd748]

U should see yahoo mb for laughs shorts are shaking in their boots making up posts lol